作者: Kimihiro Okubo , Masahiko Ichimura , Tomoya Koyama , Yutaka Susuta , Hitoshi Izaki
DOI: 10.1517/14656566.2015.1085511
关键词:
摘要: Background: Although second-generation antihistamines, such as bepotastine besilate, are recommended a first-line treatment option for adult perennial allergic rhinitis (PAR), few non-sedating antihistamines safe children.Objective: A double-blind, placebo-controlled, comparative study of 473 pediatric PAR patients (7 – 15 years old) to determine the superiority and safety besilate (10 mg twice daily) relative placebo improved total individual nasal symptom scores compared with baseline.Research design methods: Subjects were randomized (n = 233) or 240, 10 orally daily 2 weeks). Interference life by was assessed measuring change in from baseline.Results: Bepotastine superior terms scores, overall symptoms baseline values. Subgroup analyses demonstrated bepotasti...